Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline
Lund, Sweden, September 2, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announces that the Company, in order to enable further progress, will begin evaluating potential financing alternatives, which may include issuance of equity. Alligator’s board has appointed financial advisors and the Company has received support from certain of the Company's largest shareholders for continued funding of the Company. To give Alligator’s new and experienced management team the right opportunities to develop the Company, the Board's current assessment is that working capital will